Publication: Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.
dc.contributor.author | Gayoso, J | |
dc.contributor.author | Balsalobre, P | |
dc.contributor.author | Pascual, M J | |
dc.contributor.author | Castilla-Llorente, C | |
dc.contributor.author | Lopez-Corral, L | |
dc.contributor.author | Kwon, M | |
dc.contributor.author | Serrano, D | |
dc.contributor.author | Piñana, J L | |
dc.contributor.author | Herrera, P | |
dc.contributor.author | Ferra, C | |
dc.contributor.author | Pascual, C | |
dc.contributor.author | Heras, I | |
dc.contributor.author | Montesinos, P | |
dc.contributor.author | Zabalza, A | |
dc.contributor.author | Bento, L | |
dc.contributor.author | Figuera, A | |
dc.contributor.author | Buño, I | |
dc.contributor.author | Diez-Martin, J L | |
dc.contributor.funder | Ministry of Economy and Competitiveness ISCIII-FIS | |
dc.contributor.funder | ERDF (FEDER) Funds from the European Commission, ‘A way of making Europe | |
dc.contributor.funder | Asociación Española Contra el Cáncer (AECC) | |
dc.contributor.funder | Fundación Mutua Madrileña (FMM) | |
dc.date.accessioned | 2023-01-25T08:32:23Z | |
dc.date.available | 2023-01-25T08:32:23Z | |
dc.date.issued | 2016-05-09 | |
dc.description.abstract | Relapsed or refractory Hodgkin lymphoma (advanced HL) still remains a therapeutic challenge. Recently, unmanipulated haploidentical related donor transplant with reduced conditioning regimen (HAPLO-RIC) and post-transplant cyclophosphamide (PT-Cy) as GvHD prophylaxis has became a promising rescue strategy potentially available to almost every patient. This paper reports our multicenter experience using an IV busulfan-based HAPLO-RIC regimen and PT-Cy in the treatment of 43 patients with advanced HL. Engraftment occurred in 42 patients (97.5%), with a median time to neutrophil and platelet recovery of 18 and 26 days. Cumulative incidences of grades II-IV acute GvHD and chronic GvHD were 39% and 19%, respectively. With a median follow-up of 25.5 months for survivors, 27 patients are alive, with 22 of them disease free. Cumulative incidences of 1-year non-relapse mortality and relapse at 2 years were 21% and 24%, respectively. The estimated 2-year event-free survival (EFS) and overall survival (OS) were 48% and 58%, respectively. CR prior to HAPLO-RIC correlated with better EFS (78.5% vs 33.5%; P=0.015) and OS (86% vs 46%; P=0.044). Our findings further confirm prior reports using HAPLO-RIC in advanced HL in a multicenter approach employing an IV busulfan-based conditioning regimen. | |
dc.description.sponsorship | This work was partially supported by the Ministry of Economy and Competitiveness ISCIII-FIS grants PI11/00708, PI14/01731 and RD12/0036/0061, co-financed by ERDF (FEDER) Funds from the European Commission, ‘A way of making Europe’, as well as grants from Asociación Española Contra el Cáncer (AECC) and Fundación Mutua Madrileña (FMM). | |
dc.description.version | Si | |
dc.identifier.citation | Gayoso J, Balsalobre P, Pascual MJ, Castilla-Llorente C, López-Corral L, Kwon M, et al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplant. 2016 Oct;51(10):1307-1312 | |
dc.identifier.doi | 10.1038/bmt.2016.115 | |
dc.identifier.essn | 1476-5365 | |
dc.identifier.pmid | 27159177 | |
dc.identifier.uri | http://hdl.handle.net/10668/10067 | |
dc.issue.number | 10 | |
dc.journal.title | Bone marrow transplantation | |
dc.journal.titleabbreviation | Bone Marrow Transplant | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Regional de Málaga | |
dc.page.number | 1307-1312 | |
dc.provenance | Realizada la curación de contenido 13/03/2025 | |
dc.publisher | Nature Publishing Group | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Multicenter Study | |
dc.relation.projectID | PI11/00708 | |
dc.relation.projectID | PI14/01731 | |
dc.relation.projectID | RD12/0036/0061 | |
dc.relation.publisherversion | https://doi.org/10.1038/bmt.2016.115 | |
dc.rights.accessRights | Restricted Access | |
dc.subject | Spain | |
dc.subject | Survival Analysis | |
dc.subject | Transplantation Conditioning | |
dc.subject | Transplantation, Haploidentical | |
dc.subject | Young Adult | |
dc.subject.decs | Busulfano | |
dc.subject.decs | Trasplantes | |
dc.subject.decs | Informe de Investigación | |
dc.subject.decs | Neutrófilos | |
dc.subject.decs | Plaquetas | |
dc.subject.decs | Ciclofosfamida | |
dc.subject.decs | Enfermedad de Hodgkin | |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Busulfan | |
dc.subject.mesh | Cyclophosphamide | |
dc.subject.mesh | Female | |
dc.subject.mesh | Graft vs Host Disease | |
dc.subject.mesh | Hodgkin Disease | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Salvage Therapy | |
dc.title | Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. | |
dc.type | research article | |
dc.volume.number | 51 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format